Cytiva Provides Arranta Bio with Single-Purpose Manufacturing Platform for mRNA Products

Arranta Bio will use Cytiva’s FlexFactory single-use manufacturing platform to produce mRNA vaccines.

Cytiva announced on January 25, 2022 that it will supply its FlexFactory single-use manufacturing platform to Arranta Bio, a contract development and manufacturing organization (CDMO), for the manufacture of messenger RNA (mRNA) vaccines.

Arranta is adding $10 million to its $100 million investment in its new facility in Watertown, Massachusetts. The additional $10 million will be used to open dedicated space for mRNA manufacturing, lipid nanoparticle (LNP) formulation and drug product filling. With the expansion of the Watertown facility, Arranta will have the ability to offer an end-to-end platform for current Good Manufacturing Practice (CGMP) manufacturing of mRNA products. The new space, scheduled to open within six months, will include in vitro transcription, mRNA purification, LNP formulation and aseptic filling. The first GMP production run is expected in the third quarter of 2022.

“Arranta offers mRNA developers something unique: an integrated suite of complementary services from a single vendor. Cytiva’s solutions give us the flexibility and modularity to offer our customers custom manufacturing. With the addition of Cytiva’s robotic aseptic filling solutions, we are truly an end-to-end single point of contact CDMO, reducing overall complexity, cost and time for the product innovator,” said Mark Bamforth , Executive Chairman and CEO of Arranta. , in a company press release.

Cytiva had acquired the aseptic business of Canadian company Vanrx in early 2021, which completed its biomanufacturing workflow and enables the company to offer solutions from “idea to injection”.

“Our agreement with Arranta marks the first use of our full suite of solutions in mRNA manufacturing. We have developed our platform to work with a multitude of modalities beyond traditional mAbs [monoclonal antibodies], such as cell and gene therapies, plasmid DNA and now mRNA. It is exciting to support this next generation of therapies that will benefit patients around the world and to fulfill our company’s mission to advance and accelerate therapies,” said Olivier Loeillot, Vice President of Bioprocess at Cytiva, in the press release.

Source: Cytiva

Comments are closed.